The best selected 2-variable model predicting overall survival in DLBCL was the combination of the major histocompatibility (MHC) class II antigen, HLA-DRB, and the cell cycle associated gene, MYC. This evidence concerns the gene HLA-DRB1 and diffuse large B-cell lymphoma.